Breaking News, Collaborations & Alliances

Evecxia, Quotient Sciences Complete Clinical Milestone for Depression Drug

Quotient Sciences’ modified release capabilities enhance performance of EVX-101.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia’s drug candidate EVX-101, which is in development for major depressive disorder (MDD). Quotient Sciences’ Translational Pharmaceutics platform was used to develop and optimize the drug delivery mechanism of the EVX-101 technology and was a driving force behind the success of the clinical testing program. Evecxia is the f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters